Basic Information
| Drug ID | DDPD00180 |
|
| Drug Name | Flunisolide | |
| Molecular Weight | 434.4977 | |
| Molecular Formula | C24H31FO6 | |
| CAS Number | 3385-03-3 | |
| SMILES | [H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO | |
| External Links | ||
| DRUGBANK | DB00180 | |
| PubChem Compound | 82153 | |
| PDR | 1176 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 1.1 | - | 1.1 | - | DRUGBANK |
| Melting Point | 228.0 | ℃ | 226-230 | ℃ | American Cyanamid Co.; British Patent 933,867; August 14, 1963. |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Clearance | 0.57 | L/h/kg | 9.5 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.1 | L/kg | 1.08 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 1.8 | h | 1.8 | h | DRUGBANK | Half-life | 1.7 | h | 1.68 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Protein Binding | 40.0 | % | ~40 | % | PO, oral; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 0.64 | mg/day | 640 | mcg/day | inhalation, IH | Aerospan | flunisolide | PDR |
| Max dose for children | 100.0 | mcg/nostril/day | 100 | mcg/nostril/day | nasal spray | Aerospan | flunisolide | PDR |
| Max dose for children | 0.32 | mg/day | 320 | mcg/day | inhalation, IH | Aerospan | flunisolide | PDR |
| Max dose for children | 100.0 | mcg/nostril/day | 100 | mcg/nostril/day | nasal spray | Aerospan | flunisolide | PDR |
| Max dose for adolescents | 0.64 | mg/day | 640 | mcg/day | inhalation, IH | Aerospan | flunisolide | PDR |
| Max dose for adolescents | 200.0 | mcg/nostril/day | 200 | mcg/nostril/day | nasal spray | Aerospan | flunisolide | PDR |
| Max dose for adolescents | 0.64 | mg/day | 640 | mcg/day | inhalation, IH | Aerospan | flunisolide | PDR |
| Max dose for adolescents | 100.0 | mcg/nostril/day | 100 | mcg/nostril/day | nasal spray | Aerospan | flunisolide | PDR |
| Max dose for adults | 0.64 | mg/day | 640 | mcg/day | inhalation, IH | Aerospan | flunisolide | PDR |
| Max dose for adults | 200.0 | mcg/nostriL/day | 200 | mcg/nostriL/day | nasal spray | Aerospan | flunisolide | PDR |
| Max dose for geriatric | 0.64 | mg/day | 640 | mcg/day | inhalation, IH | Aerospan | flunisolide | PDR |
| Max dose for geriatric | 0.2 | mg/day | 200 | mcg/nostril/day | nasal spray | Aerospan | flunisolide | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1